Continuous-infusion cyclophosphamide in combination with teniposide and dexamethasone in refractory myeloma
| Autor: | Franco Leoni, Roberto Caporale, F. Salti, Pierluigi Rossi Ferrini, Stefania Ciolli |
|---|---|
| Rok vydání: | 1992 |
| Předmět: |
Adult
Male Cancer Research medicine.medical_specialty Cyclophosphamide medicine.medical_treatment Gastroenterology Dexamethasone Refractory Internal medicine Antineoplastic Combined Chemotherapy Protocols medicine Humans Infusions Intravenous Survival rate Aged Teniposide Aged 80 and over Chemotherapy Beta-2 microglobulin business.industry Hematology Middle Aged Surgery Survival Rate Oncology Toxicity Female business Multiple Myeloma medicine.drug |
| Zdroj: | Leukemialymphoma. 7(5-6) |
| ISSN: | 1042-8194 |
| Popis: | Forty-three consecutive patients with refractory myeloma, median age 60, received monthly courses of teniposide 30 mg/m2 i.v. on days 1-2, dexamethasone 40 mg i.v. on days 1-7 and cyclophosphamide 200 mg/m2 by continuous i.v. infusion for seven days. Major response (decrease > 50% of M-protein) was achieved in 18 of 37 evaluable patients and minor response in 9, with an overall response rate of 73%. Response was irrespective of disease status, time from diagnosis and previous treatments, while beta 2 microglobulin > 6 mg/l was a powerful prognostic factor. All patients experienced transient granulocytopenia but extramedullary toxicity was negligible. Median survival of the whole group is 20 months, with 74% of responding patients projected to be alive at 30 months. In refractory myeloma cyclophosphamide appears to be more active when given by continuous infusion. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|